Accelerating Texas K12 education: The Future of Innovation in School Districts

In this episode of Accelerating Texas K12 Education, host, JW Marshall, of Summit K12, is joined by Doug Roberts, Founder/CEO of, the Institute for Education Innovation. The two discussed what dive into what it is that Robert’s organization does at both a local and national level. Robert’s also offereds insights on into the past, present, and future of innovation in districts, and as well as how districts can continue to build on positive changes that began in 2021.

Robert’s is both a father and a husband, but beyond that, he is the founder and CEO of the Institute for Education Innovation, a institution dedicated to addressing and tackling education’s most pressing issues and providing sustainable solutions

“Why I love it is I happen to think school superintendents are among the most remarkable people on the planet and I am honored that I get to spend time with them and get to connect them to some of these amazing folks who lead and have started organizations in the K12 industry,” explained Robert’s.

Institute for Education Innovation works with superintendents all around the country, from aspiring superintendents or season veterans. They host three3 superintendent summits a year, where superintendents and chief academic officers work together to tackle education’s biggest issues. “The professional development that comes out of it is getting to share those stories across geographical regions and boundaries.”

Especially in regards to the fall of 2021, districts all over were dealing with political issues related to Covid-19. However, it turns out there were so many common threads that as a group they were able to find viable solutions to help districts throughout the U.S. survive and persist.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More